Message boards index | Help | Search messages | Sign in


+ UKCAB + Public area + News, events, announcments + Stakeholder testing of Bedaquiline and Delamanid Policy For MDR-XDR-TB

Stakeholder testing of Bedaquiline and Delamanid Policy For MDR-XDR-TB

Print
Pages: 1

Forum Link
Member
Posts: 122
Stakeholder testing of Bedaquiline and Delamanid Policy For MDR-XDR-TB
Posted on: March 5 2015, 07:34 am

This is forwarded from the INF CRG...

Dear Clinical Reference Group Stakeholder,

We are writing to request your views on the draft Commissioning Policy for Bedaquiline and Delamanid for defined patients with MDR-XDR-TB developed by the Infectious Diseases Clinical Reference Group. The draft policy is attached (see below).

This draft Commissioning Policy is an update on the previous draft Commissioning Policy for Bedaquiline for defined patients with MDR-XDR-TB and now includes Delamanid. The changes in this updated policy have been highlighted for easier reference.

The response form is attached to this email (see below) and the details of the CRG and title of the policy have been completed for you to assist your response. Please note that in order for these responses to be processed we can only access responses that are submitted using this form (see below).

Please could you ensure all responses are submitted by return by no later than Wednesday 18 March 2015 and submitted to the following email address: england.npoc-bloodandinfection@nhs.net

Please send your response by email with the following title in the subject line "INF CRG: Stakeholder testing of Bedaquiline and Delamanid Policy"

Please note that all proposals from the Clinical Reference Group constitute draft advice to NHS England and have no force until formally approved by NHS England.  This testing process does not seek to pre-empt or replicate the full public consultation on approved proposals.

Kind regards,
Infectious Diseases Clinical Reference Group
Logged
Simon Collins
Global Moderator
Posts: 651
Re: Stakeholder testing of Bedaquiline and Delamanid Policy For MDR-XDR-TB
Reply #1 on: March 5 2015, 07:48 am

Thanks Paul, i-Base is likely to respond and it would be good if the CAB and other groups do too. I don;t know why these consultations have such short deadlines that are not helpful.
Logged

Print
Pages: 1

+ UKCAB + Public area + News, events, announcments + Stakeholder testing of Bedaquiline and Delamanid Policy For MDR-XDR-TB